Allogene Therapeutics
ALLO
156 hedge funds and large institutions have $460M invested in Allogene Therapeutics in 2024 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 60 increasing their positions, 47 reducing their positions, and 27 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 47
20% more capital invested
Capital invested by funds: $385M → $460M (+$75.5M)
0.51% less ownership
Funds ownership: 79.12% → 78.61% (-0.51%)
10% less funds holding
Funds holding: 174 → 156 (-18)
11% less call options, than puts
Call options by funds: $354K | Put options by funds: $399K
63% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$10.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$6.91M |
| 3 |
ECM
ExodusPoint Capital Management
New York
|
+$3.58M |
| 4 |
BlackRock
New York
|
+$3.54M |
| 5 |
Goldman Sachs
New York
|
+$1.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$8.97M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.28M |
| 3 |
Renaissance Technologies
New York
|
-$2.95M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.54M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.05M |
ALLO Hedge Fund Activity: Q3 2024 in Review
156 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2024, worth a combined $460M — up 20% from $385M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ALLO and 10 opened new positions — a net loss of 17 holders — while 47 trimmed existing stakes and 60 added.
The largest buyer was Lynx1 Capital Management, adding an estimated $10.6M. The largest seller was Boxer Capital, exiting entirely with an estimated $8.97M sold.
- 156 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2024, down from 174 in Q2 2024.
- Funds reported $460M of Allogene Therapeutics stock for Q3 2024, up 20% quarter-over-quarter.
- 10 funds opened new Allogene Therapeutics positions in Q3 2024 and 27 closed out, a net change of -17 holders.
- The largest Allogene Therapeutics buyer in Q3 2024 was Lynx1 Capital Management, an estimated $10.6M added.
- The largest Allogene Therapeutics seller in Q3 2024 was Boxer Capital, an estimated $8.97M sold.
Based on aggregated 13F filings for Q3 2024.